GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.
Financial Results:
Glaxosmithkline Pharmaceuticals Ltd reported Revenues for Q1FY25 of ₹815.00 Crores up from ₹762.00 Crore year on year, a rise of 6.96%.
Total Expenses for Q1FY25 of ₹600.00 Crores down from ₹634.00 Crores year on year, a fall of 5.36%.
Consolidated Net Profit of ₹182.00 Crores up 37.88% from ₹132.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹10.76, up 37.77% from ₹7.81 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.